Four-week IgE/baseline IgE ratio combined with tryptase predicts clinical outcome in omalizumab-treated children with moderate-to-severe asthma.

Objective: The aim of this study was to investigate the feasibility of the 4-week IgE/baseline IgE ratio and tryptase to predict the clinical efficacy of omalizumab in the treatment of pediatric moderate-to-severe asthma. Methods: Moderate-to-severe asthma patients were selected, and their baseline IgE levels were recorded, and the IgE levels were tested again after 4 weeks of treatment with omalizumab to calculate the 4-week IgE/baseline IgE ratio. Serum tryptase was measured. Treatment efficacy was assessed. Patients were divided into response and non-response groups. Receiver operating characteristic curves were plotted for the sensitivity and specificity of the indices in predicting response to omalizumab treatment. Results: Serum total IgE levels increased to 655.89 IU/mL, serum tryptase was 5.31 ng/mL after 4 weeks of treatment, which was higher than at baseline. There was a significant difference in total serum IgE between children in response and non-response groups after 4 weeks of treatment. The response group children had a higher 4-week IgE/baseline IgE ratio, whereas tryptase was lower. Combined metrics had moderate predictive value for the efficacy of omalizumab therapy. Conclusion: The 4-week IgE/baseline IgE ratio combined with tryptase can predict, to a certain extent, the clinical efficacy of omalizumab in the treatment of pediatric moderate-to-severe asthma.